公开(公告)号：US20230272406A1

公开(公告)日：2023-08-31

申请号：US17936377

申请日：2022-09-28

Applicant: BioNTech SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG

Inventor： Alexandra Orlandini Von Niessen ,  Stephanie Fesser ,  Britta Vallazza ,  Tim Beissert ,  Andreas Kuhn ,  Ugur Sahin ,  Marco Alexander Poleganov

IPC: C12N15/67 ,  A47B3/00 ,  A47B13/02 ,  A47B33/00 ,  A47B43/00 ,  A47B77/02 ,  A47B77/06 ,  A47B77/08 ,  A47B77/16 ,  A47B77/18 ,  A47B95/00 ,  A47C4/00 ,  A47C4/08 ,  A47C7/00 ,  A47K3/28 ,  B60B33/00 ,  E04H1/12 ,  F16C11/04 ,  C12N5/0735 ,  C12N15/113 ,  C12N15/90

CPC classification number: C12N15/67 ,  A47B3/002 ,  A47B13/02 ,  A47B33/00 ,  A47B43/00 ,  A47B77/022 ,  A47B77/06 ,  A47B77/08 ,  A47B77/16 ,  A47B77/18 ,  A47B95/00 ,  A47B95/008 ,  A47C4/00 ,  A47C4/08 ,  A47C7/002 ,  A47C7/006 ,  A47K3/284 ,  B60B33/00 ,  E04H1/1266 ,  F16C11/04 ,  C12N5/0606 ,  C12N15/113 ,  C12N15/90 ,  A47B2003/006 ,  A47B2200/0018 ,  C12N2310/113

Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3′-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.

公开(公告)号：US12133899B2

公开(公告)日：2024-11-05

申请号：US17988742

申请日：2022-11-16

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: A61K48/00 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/00 ,  A61K39/12 ,  A61K39/215 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34 ,  A61K38/00

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20240110214A1

公开(公告)日：2024-04-04

申请号：US18266135

申请日：2021-12-07

Applicant: BioNTech SE

Inventor： Thomas Ziegenhals ,  Andreas Kuhn ,  Stephanie Fesser

IPC: C12P19/34 ,  A61K31/7115

CPC classification number: C12P19/34 ,  A61K31/7115

Abstract: The present disclosure provides technologies for performing in vitro transcription that can generate product RNA preparations with reduced levels of certain contaminants (e.g., aberrant products), and particularly of double-stranded RNA (dsRNA).

公开(公告)号：US20240002127A1

公开(公告)日：2024-01-04

申请号：US17920569

申请日：2021-04-16

Applicant: Pfizer Inc. ,  BioNTech SE

Inventor： Marjoh Nauta ,  Dirk Jozef Peeters ,  Tom Frank Steven Van Doorslaer ,  Advait Vijay Badkar ,  Ramin Darvari ,  Nicholas William Warne ,  James Jean ,  Danny Pierre G. Hendrikse ,  Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: B65D81/127 ,  A61K39/215 ,  B65D77/04 ,  B65D81/38

CPC classification number: B65D81/127 ,  A61K39/215 ,  A61K2039/55555 ,  B65D81/3813 ,  B65D77/0413

Abstract: The present disclosure relates to the fields of packaging, transportation, and storage of temperature-sensitive materials, such as biological and/or pharmaceutical products. Various aspects of such packaging, transportation, and storage are provided herein for ultra-low temperature materials useful for the treatment and/or prevention of disease. The present disclosure also provides packaging materials, methods of transportation, and methods of storage for maintaining biological and/or pharmaceutical materials at ultra-low temperatures in order to maintain the integrity of the materials. The present disclosure further relates to the field of RNA to prevent or treat coronavirus infection.

公开(公告)号：US20250011797A1

公开(公告)日：2025-01-09

申请号：US18737443

申请日：2024-06-07

Applicant: BioNTech SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG

Inventor： Florian Eberle ,  Ugur Sahin ,  Andreas Kuhn ,  Britta Vallazza ,  Mustafa Diken

IPC: C12N15/68 ,  A61K39/00 ,  A61K48/00 ,  C12N15/67 ,  C12N15/70 ,  C12N15/85 ,  C12P19/34 ,  C12P21/00

Abstract: The present invention relates to nucleic acid molecules containing poly(dA:dT) regions which are stabilized in E.coli, methods of propagating such nucleic acid molecules in E.coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly(dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.

公开(公告)号：US20240075165A1

公开(公告)日：2024-03-07

申请号：US17988742

申请日：2022-11-16

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: A61K48/00 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/00 ,  A61K39/12 ,  A61K39/215 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

CPC classification number: A61K48/0066 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/5123 ,  A61K9/5146 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/215 ,  A61K48/0033 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34 ,  A61K38/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  C12N2770/18022 ,  C12N2770/18034 ,  C12N2770/18071 ,  C12N2770/20034

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20230075979A1

公开(公告)日：2023-03-09

申请号：US17698829

申请日：2022-03-18

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: A61K39/215 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K9/51 ,  A61P31/14 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US12054723B2

公开(公告)日：2024-08-06

申请号：US16898176

申请日：2020-06-10

Applicant: BioNTech SE ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gG

Inventor： Florian Eberle ,  Ugur Sahin ,  Andreas Kuhn ,  Britta Vallazza ,  Mustafa Diken

IPC: C12N5/00 ,  A61K39/00 ,  A61K48/00 ,  C12N15/67 ,  C12N15/68 ,  C12N15/70 ,  C12N15/85 ,  C12P19/34 ,  C12P21/00

CPC classification number: C12N15/68 ,  A61K39/00 ,  A61K48/0066 ,  C12N15/67 ,  C12N15/70 ,  C12N15/85 ,  C12P19/34 ,  C12P21/00 ,  A61K2039/53 ,  C12N2830/50

Abstract: The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in E.-coli, methods of propagating such nucleic acid molecules in E. coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.

公开(公告)号：US20230183769A1

公开(公告)日：2023-06-15

申请号：US17893742

申请日：2022-08-23

Applicant: BioNTech SE

Inventor： Irena Rabe ,  Maximilian Buff ,  Thomas Ziegenhals ,  Johanna Drögemüller ,  Andreas Kuhn ,  Stephanie Fesser ,  Rodney Gene Combs ,  Nicole Eschmann ,  Jennifer Ann Schoborg Romine ,  Jenna Kathryn Williamson

IPC: C12P19/34 ,  C12N9/12

CPC classification number: C12P19/34 ,  C12N9/1247

Abstract: The present disclosure provides technologies for in vitro transcription reactions, particularly for production of pharmaceutical grade RNA, and in some embodiments for large scale production.

公开(公告)号：US20230073461A1

公开(公告)日：2023-03-09

申请号：US17699035

申请日：2022-03-18

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: A61K39/12 ,  A61K31/7105 ,  A61K31/7115 ,  A61K31/712 ,  A61K9/127 ,  A61K9/51 ,  A61P31/14 ,  B82Y5/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.